Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results



    
                           Wednesday, May 6, 2009
                                9:00 a.m. EDT

                               1-800-814-4860

                Webcast: http://www.nucryst.com/web_casts.htm
    

    CALGARY, April 29 /CNW/ - NUCRYST Pharmaceuticals Corp. invites analysts
and investors to participate in a briefing on Wednesday, May 6, 2009, with
David B. Holtz, Interim President & Chief Executive Officer, and Chief
Financial Officer, regarding the Company's 2009 first quarter results.
    The briefing, via conference call, is set for 9:00 a.m. EDT. To
participate, please call the toll-free number 1-800-814-4860. In addition to
standard disclosure over wire services, a news release with the first quarter
results will be posted on the NUCRYST web site prior to the call. To listen to
the call live on the Internet, please go to
http://www.nucryst.com/web_casts.htm.
    The briefing will be recorded and available for re-broadcast on demand
for seven days by dialing 1-877-289-8525. Callers will need to provide the
operator with the following reservation number: 21305201 followed by the
number sign. An audio file of the call will also be archived on the NUCRYST
web site.

    About NUCRYST Pharmaceuticals

    NUCRYST Pharmaceuticals Corp. (NASDAQ:   NCST; TSX: NCS) develops,
manufactures and commercializes medical products that fight infection and
inflammation using SILCRYST(TM), its patented atomically disordered
nanocrystalline silver technology. NUCRYST licensed world-wide rights for
SILCRYST(TM) wound care coating products to Smith & Nephew plc, which markets
these products in over 30 countries under their Acticoat(TM) trademark.
NUCRYST has developed its proprietary nanocrystalline silver in a powder form,
referred to as NPI 32101, for use in medical devices and as an active
pharmaceutical ingredient.

    
    Acticoat(TM) is a trademark of Smith & Nephew plc
    SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
    

    %SEDAR: 00023031E




For further information:

For further information: David Wills, Gillian McArdle, Investor
Relations, NUCRYST Pharmaceuticals Corp., (416) 504-8464, info@nucryst.com

Organization Profile

NUCRYST PHARMACEUTICALS CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890